Combination Tx with DC/AML fusion veTcs and SAR eradicates AML engraftment in a xenograft murine model. NSG mice were inoculated with patient-derived AML cells (n = 25). After detection of human engraftment in the peripheral blood, animals were treated on day 28 after AML inoculation with either veTcs or SAR or combination of both; no Tx (n = 5), uTcs + IgG (n = 5), uTcs + SAR (n = 5), veTcs + IgG (n = 5), veTcs + SAR (n = 5). Organ assessment for AML burden was performed 43 days after starting Tx (71 days after inoculation). (A) Patient-derived xenograft schema. (B) Spleen and bone marrow samples analyzed by flow cytometry for hCD45⁺CD3⁺ T cells and hCD45⁺CD38⁺ AML. Mean with SEM is shown. Statistical analysis was performed using GraphPad Prism 10.0. Pairwise comparison was performed using Kruskal-Wallis test, with Dunn multiple comparisons and Benjamini-Hochberg FDR correction. A P value < .05 is considered statistically significant. ∗P ≤ .05; ∗∗P ≤ .01; ∗∗∗P ≤ .001. (C) Number of animals with the indicated percentage of hCD38⁺ cells in the bone marrow as depicted in panel B, Fisher exact test. (D) Representative images demonstrating cell morphology consistent with blasts in an untreated mouse bone marrow preparation. Tx, treatment.